EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment outcomes in new daily persistent headache in children and adolescents

Behandlungsergebnisse bei neuem täglich persistierendem Kopfschmerz bei Kindern und Jugendlichen

Nassim Abuhalaweh iD, Amy A Gelfand iD, Morgan Evans iD, Blanca Marquez de Prado iD, Carlyn Patterson Gentile iD, Nichelle Raj, Andrew D Hershey iD, Christina L Szperka iD

Cephalalgia · 2026-06 · 46 (6)

DOI: 10.1177/03331024261426562 ↗

Auf einen Blick

In einer retrospektiven Aktenanalyse bei 165 Kindern und Jugendlichen mit NDPH waren frühe Übergangstherapien am häufigsten mit Nutzen verbunden. Längere Zeit bis zur ersten Therapie war mit geringerer Besserung nach 1 Jahr assoziiert.

Fragestellung

Welche Behandlungsergebnisse zeigen sich bei Kindern und Jugendlichen mit neuem täglich persistierendem Kopfschmerz (NDPH)?

Methode

Retrospektive Aktenanalyse bei 5–17-Jährigen mit abrupt einsetzendem, kontinuierlichem Kopfschmerz seit mindestens 1 Monat; Auswertung von Therapien bis zum Abbruch der Kontinuität und anhaltender Besserung.

Ergebnisse

165 Patient:innen. Erste Übergangstherapie: Nutzen bei 62/108 (57%). Erstes Supplement: 36/118 (31%) Nutzen, 3/118 (3%) negative Outcomes. Erstes verschreibungspflichtiges Prophylaktikum: 37/106 (35%) Nutzen, 25/106 (24%) negative Outcomes. OnabotulinumtoxinA: 14/20 (70%) Nutzen, 0% negative Outcomes.

Schlussfolgerung der Autor:innen

Kinder und Jugendliche mit neu aufgetretenem kontinuierlichem Kopfschmerz erfahren Behandlungsverzögerungen, die mit schlechteren Ergebnissen verbunden sind. Die Autor:innen empfehlen, Übergangstherapien möglichst früh zusammen mit Prophylaxen zu erwägen.

Kernaussagen

  • Frühe Übergangstherapien waren am häufigsten mit Nutzen verbunden.
  • Längere Zeit bis zur ersten Therapie senkte die Odds für Besserung nach 1 Jahr.
  • OnabotulinumtoxinA zeigte bei 14/20 Nutzen ohne negative Outcomes.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, online erschienen am 19.06.2026. Verfasst von Nassim Abuhalaweh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Headache Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NICHD NIH HHS, International Headache Society.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

New daily persistent headache (NDPH) is a primary headache disorder that often presents in adolescence. Presently, there is no effective treatment for NDPH and a paucity of clinical trials exploring therapeutic options. In this study, we explored the relative benefit of currently used treatments to help inform future trials and clinical decision-making.

Methods

In this retrospective chart review study, patients aged 5–17 years with abrupt onset continuous headache and headache duration of at least one month (constituting NDPH or probable NDPH) were identified based on responses to a Headache Questionnaire in child neurology clinic and confirmed with chart review. We included all treatments (transitional therapy, preventive supplement, preventive medication and preventive non-medication therapy) started during continuous headache until both break in continuous headache and sustained improvement in headache were achieved. For treatments tried by at least 10 patients and for the first treatment tried in each category, we calculated proportions of any documented benefit, including “Significant” (≥30% improvement lasting ≥4 weeks) and “Some improvement” (all other improvement) and proportions of negative outcome (those with worsened headaches or side effects warranting discontinuation), as well as median time to treatment. We used multivariable regression modeling to examine for factors associated with headache outcomes. Treatments may have overlapped.

Results

Of the 165 patients, the largest proportion of patients experienced benefit with the first transitional therapy (62/108; 57%), which was usually intravenous medications ± oral corticosteroids. The first supplement tried, usually riboflavin ± magnesium, offered benefit in (36/118; 31%), with few negative outcomes (3/118; 3%). The first prescription preventive tried, usually amitriptyline or topiramate, offered similar benefit (37/106; 35%) as the first supplement, but with more negative outcomes (25/106; 24%). Despite being tried after oral preventives, onabotulinumtoxinA injections offered benefit to the largest proportion of patients (14/20; 70%) without negative outcomes (0%). Overall, the time to first therapy was weeks to months into continuous headache: shortest for transitional therapies (median = 49 days, interquartile range = 17–92 days), and longest for non-medication therapies (median = 144 days, interquartile range = 61–381 days). Increased time to any first treatment was associated with decreased odds of headache improvement at one-year follow-up (odds ratio = 0.823, 95% confidence interval = 0.715–0.946, p = 0.006).

Conclusions

Children and adolescents with new onset continuous headache experience treatment delays which are associated with worse outcomes. Clinicians should consider use of transitional therapies in combination with preventive treatments as early as possible. Prospective natural history studies and trials are needed to improve treatment outcomes for pediatric patients with NDPH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Headache DisordersHumansAdolescentChildTreatment OutcomeRetrospective StudiesMaleFemaleChild, Preschool

Stichwörter der Autor:innen

headachenew daily persistent headachepediatrictreatment

Autor:innen und Institutionen

  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Pediatric Headache Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Department of Neurology, Child & Adolescent Headache Program, University of California San Francisco, San Francisco, CA, USA.
  • Division of Neurology, Cincinnatti Children's Hospital & Medical Center, San Cincinnatti, OH, USA.
  • Department of Pediatrics, University of Cincinnati School of Medicine, San Cincinnatti, OH, USA.

ORCID-Profile: Nassim Abuhalaweh, Amy A Gelfand, Morgan Evans, Blanca Marquez de Prado, Carlyn Patterson Gentile, Andrew D Hershey, Christina L Szperka

Förderung

  • NINDS NIH HHS
  • NICHD NIH HHS
  • International Headache Society

Zitieren

APA

Abuhalaweh, N., Gelfand, A. A., Evans, M., Marquez de Prado, B., Patterson Gentile, C., Raj, N., Hershey, A. D., & Szperka, C. L. (2026). Treatment outcomes in new daily persistent headache in children and adolescents. Cephalalgia, 46(6). https://doi.org/10.1177/03331024261426562

Vancouver

Abuhalaweh N, Gelfand AA, Evans M, Marquez de Prado B, Patterson Gentile C, Raj N, et al. Treatment outcomes in new daily persistent headache in children and adolescents. Cephalalgia. 2026;46(6). doi:10.1177/03331024261426562

BibTeX
@article{Abuhalaweh2026,
  author = {Abuhalaweh, Nassim and Gelfand, Amy A and Evans, Morgan and Marquez de Prado, Blanca and Patterson Gentile, Carlyn and Raj, Nichelle and Hershey, Andrew D and Szperka, Christina L},
  title = {Treatment outcomes in new daily persistent headache in children and adolescents},
  journal = {Cephalalgia},
  year = {2026},
  volume = {46},
  number = {6},
  doi = {10.1177/03331024261426562}
}
Kostenlos starten →